HUP0203195A2 - Redox reverzibilis HCV-fehérjék natívhoz hasonló konformációval - Google Patents

Redox reverzibilis HCV-fehérjék natívhoz hasonló konformációval

Info

Publication number
HUP0203195A2
HUP0203195A2 HU0203195A HUP0203195A HUP0203195A2 HU P0203195 A2 HUP0203195 A2 HU P0203195A2 HU 0203195 A HU0203195 A HU 0203195A HU P0203195 A HUP0203195 A HU P0203195A HU P0203195 A2 HUP0203195 A2 HU P0203195A2
Authority
HU
Hungary
Prior art keywords
hcv proteins
conformation
native
redox reversible
hcv
Prior art date
Application number
HU0203195A
Other languages
English (en)
Inventor
Alfons Bosman
Erik Depla
Geert Maertens
Original Assignee
Innogenetics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics N.V. filed Critical Innogenetics N.V.
Publication of HUP0203195A2 publication Critical patent/HUP0203195A2/hu
Publication of HUP0203195A3 publication Critical patent/HUP0203195A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány tárgyát HCV-fehérjék képezik, amelyekben cisztein-oldalláncok reverzibilisen védettek a tisztítás során. Végső soron atisztítási eljárás HCV-fehérjéket eredményez biológiai aktivitással,és amelyeknek natívhoz hasonló a konformációja megfelelő epitópokkal.A találmány tárgya továbbá drog-szkrínelési eljárás ezen HCV-fehérjékalkalmazásával, és diagnosztikai és terápiás alkalmazások, mintpéldául oltóanyagok és drogok. Ó
HU0203195A 1999-10-27 2000-10-25 Redox reversible hcv proteins with native-like conformation HUP0203195A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99870225 1999-10-27
US16928899P 1999-12-07 1999-12-07
PCT/EP2000/010499 WO2001030815A1 (en) 1999-10-27 2000-10-25 Redox reversible hcv proteins with native-like conformation

Publications (2)

Publication Number Publication Date
HUP0203195A2 true HUP0203195A2 (hu) 2002-12-28
HUP0203195A3 HUP0203195A3 (en) 2004-07-28

Family

ID=30129297

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203195A HUP0203195A3 (en) 1999-10-27 2000-10-25 Redox reversible hcv proteins with native-like conformation

Country Status (14)

Country Link
EP (1) EP1224214A1 (hu)
JP (1) JP2003513022A (hu)
CN (1) CN1384839A (hu)
AU (1) AU1144501A (hu)
BR (1) BR0015170A (hu)
CA (1) CA2387666A1 (hu)
CZ (1) CZ20021819A3 (hu)
HU (1) HUP0203195A3 (hu)
MX (1) MXPA02004052A (hu)
NZ (1) NZ518095A (hu)
PL (1) PL354990A1 (hu)
RU (1) RU2002109480A (hu)
WO (1) WO2001030815A1 (hu)
ZA (1) ZA200203169B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273348A1 (en) 2000-07-10 2002-01-21 Diosynth Rtp, Inc. Purification of human troponin i
EP1381671A2 (en) 2001-04-24 2004-01-21 Innogenetics N.V. Constructs and methods for expression of recombinant hcv envelope proteins
EP1481984A1 (en) * 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS5
BR112015023355A8 (pt) * 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
EP3756648A1 (en) * 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
AU652919B2 (en) * 1989-06-02 1994-09-15 Genetic Systems Corporation Cysteine thiol-protected peptides for use in immunoassays
US6150134A (en) * 1994-07-29 2000-11-21 Innogenetics, N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB9703406D0 (en) * 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue

Also Published As

Publication number Publication date
NZ518095A (en) 2003-09-26
WO2001030815A1 (en) 2001-05-03
RU2002109480A (ru) 2004-03-10
MXPA02004052A (es) 2002-11-07
EP1224214A1 (en) 2002-07-24
CA2387666A1 (en) 2001-05-03
CN1384839A (zh) 2002-12-11
ZA200203169B (en) 2003-09-23
BR0015170A (pt) 2002-06-25
CZ20021819A3 (cs) 2003-06-18
AU1144501A (en) 2001-05-08
PL354990A1 (en) 2004-03-22
HUP0203195A3 (en) 2004-07-28
JP2003513022A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
DE50014020D1 (de) Reinstlufteinrichtung für den Pharmazie-, Lebensmittel- und biotechnischen Bereich
ATE385806T1 (de) Fusionsproteine
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
TR200201094T2 (tr) Farmasötik maddeler olarak bisiklik amino asitler
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
CA2583764A1 (en) Thrombopoietin activity modulating compounds and methods
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
PL398391A1 (pl) Koniugat hydroksyalkiloskrobi i polipeptydu, sposób wytwarzania tego koniugatu, jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat hydroksyalkiloskrobi i polipeptydu
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
HUP0203195A2 (hu) Redox reverzibilis HCV-fehérjék natívhoz hasonló konformációval
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis
EP1283272A3 (en) Methods and means for assessing HIV envelope inhibitor therapy
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
EP1223217A4 (en) TRANSPORTER GENES OATP-B, C, D AND E
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
FR2845388B1 (fr) Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
NO20034985L (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav
NZ514691A (en) Method to type prion proteins
NO20021993L (no) Redoks-reversible HCV-proteiner med en konformasjon som ligner den native
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
ATE374260T1 (de) Asthma-assoziiertes gen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees